Skip to main content
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. — Investor Relations & Filings

Ticker · VIR ISIN · US92764N1028 US Manufacturing
Open in API
Filings indexed 727 across all filing types
Latest filing 2019-08-26 Regulatory Filings
Country US United States of America
Listing US VIR

About Vir Biotechnology, Inc.

https://www.vir.bio/

Vir Biotechnology, Inc. is a clinical-stage immunology company that leverages the immune system to treat and prevent serious infectious diseases and other conditions. The company's pipeline is built on two primary technology platforms: a next-generation antibody platform for identifying and optimizing therapeutic candidates, and the PRO-XTEN® protease-releasable masking technology for applications in oncology. Vir's main therapeutic area is infectious diseases, featuring a leading program for chronic hepatitis delta, and is complemented by strategic programs in oncology. The company has demonstrated its capabilities by developing antibody-based medicines for significant health challenges, including COVID-19 and Ebola.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings
2019-08-26 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Vir Biotechnology, Inc. to the SEC staff regarding comments on a Draft Registration Statement on Form S-1. It references the confidential draft registration statement, amendments, and addresses SEC comments on disclosures related to the company's IPO process. The document includes detailed responses to SEC comments on financial disclosures, business descriptions, and agreements, which are typical of correspondence during the SEC review of a registration statement. The presence of Form S-1 and the nature of the content indicate this is related to a registration statement filing process, not a final report or earnings release. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory correspondence and does not itself constitute a financial report, earnings release, or other specific report types. It is not a report publication announcement since it contains substantive responses, not just a notice of report availability.
2019-08-07 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a confidentially submitted Amendment No. 1 to a draft registration statement on Form S-1 filed with the SEC. It is related to the initial public offering (IPO) of Vir Biotechnology, Inc. The Form S-1 is a registration statement used for securities offerings under the Securities Act of 1933. The text includes detailed information typical of a prospectus, such as risk factors, use of proceeds, capitalization, management discussion and analysis, executive compensation, and legal matters. This is not a financial report, earnings release, or management discussion standalone document, but rather a registration statement for capital raising. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). Since this is a registration statement for an IPO, it is a capital raising document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Confidence is high given the clear identification of the document as a Form S-1 registration statement for an IPO.
2019-08-07 English
Regulatory Filings 2019
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document into any specific filing category. According to the fallback rule, when a document does not fit any specific category due to lack of information, it should be classified as Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable as a financial or regulatory report.
2019-07-25 English
Regulatory Filings 2019
Regulatory Filings
2019-07-15 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC, dated June 27, 2019, for Vir Biotechnology, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information typical of an IPO registration statement such as risk factors, use of proceeds, capitalization, dilution, management discussion and analysis, executive compensation, principal stockholders, and legal matters. This type of filing is a registration statement under the Securities Act of 1933 and is not an annual report, earnings release, or any other report type listed. It is a capital markets filing related to the company's initial public offering. According to the provided filing categories, none explicitly mention Form S-1 or IPO registration statements. The closest relevant category is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. Since an IPO registration statement is a primary capital raising document, the best fit classification is CAP. The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or notice, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2019-06-27 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.